Discovery of a potent and subtype-selective TYK2 degrader based on an allosteric TYK2 inhibitor

被引:7
|
作者
Kato, Jun-ya [1 ]
Korenaga, Shigeru [2 ]
Iwakura, Masaru [1 ]
机构
[1] ASKA Pharmaceut Co Ltd, Synthet Res Dept, 26-1 Muraoka Higashi 2 Chome, Fujisawa, Kanagawa 2518555, Japan
[2] ASKA Pharmaceut Co Ltd, Drug Discovery Dept, 26-1 Muraoka Higashi 2 Chome, Fujisawa, Kanagawa 2518555, Japan
关键词
Tyrosine kinase 2 (TYK2); Janus kinase (JAK); Proteolysis-targeting chimera (PROTAC); VonHippel-Lindau (VHL); Degrader; Allosteric TYK2 inhibitor; PROTEIN-DEGRADATION; PROTACS; MOLECULES; STRATEGY;
D O I
10.1016/j.bmcl.2022.129083
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
TYK2, a member of the JAK family of proximal membrane-bound tyrosine kinases, has emerged as an attractive target for the treatment of autoimmune diseases. Herein, we report the discovery of first-in-class potent and subtype-selective TYK2 degraders. By conjugating a TYK2 ligand from a known allosteric TYK2 inhibitor with a VHL ligand as the E3 ligase ligand via alkyl linkers of various lengths, we rapidly identified TYK2 degrader 5 with moderate TYK2 degradation activity. Degrader 5 induced TYK2 degradation without affecting the protein level of subtype kinases (JAK1, JAK2, and JAK3) in Jurkat cellular assays. Furthermore, modifying the TYK2 ligand moiety of degrader 5 yielded the more potent TYK2 degrader 37 with retained selectivity for JAKs. Our subtype -selective TYK2 degraders represent valuable chemical probes for investigating the biology of TYK2 degradation.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] TYK2 inhibition halts SpA
    Sarah Onuora
    Nature Reviews Rheumatology, 2020, 16 : 248 - 248
  • [22] TYK2 inhibition halts SpA
    Onuora, Sarah
    NATURE REVIEWS RHEUMATOLOGY, 2020, 16 (05) : 248 - 248
  • [23] TYK2 inhibition shows promise
    Villanueva, M. Teresa
    NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (09) : 668 - 668
  • [24] Approaches to TYK2 pseudokinase: A unique mode of allosteric kinase inhibition
    Moslin, Ryan
    Wrobleski, Steve
    Zhang, Yanlei
    Lin, Shuqun
    Gardner, Daniel
    Santella, Joseph
    Duncia, John
    Liu, Chunjian
    Lin, James
    Spergel, Steven
    Mertzman, Michael
    Tokarski, John
    Sun, Huadong
    Chiney, Manoj
    Elzinga, Paul
    Aranibar, Nelly
    Chimalakonda, Anjaneya
    Strnad, Joann
    Zupa-Fernandez, Adriana
    Cheng, Lihong
    Gillooly, Kathleen
    Mcintyre, Kim
    Carter, Percy
    Lombardo, Louis
    Burke, James
    Macor, John
    Weinstein, David
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 253
  • [25] Two common disease-associated TYK2 variants impact exon splicing and TYK2 dosage
    Li, Zhi
    Rotival, Maxime
    Patin, Etienne
    Michel, Frederique
    Pellegrini, Sandra
    PLOS ONE, 2020, 15 (01):
  • [26] IN-121803, a novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) for the treatment of autoimmune disease
    Chung, H.
    Park, J.
    Tae, Y.
    Hwang, I.
    Park, C.
    Kim, J.
    Lee, K.
    Kim, J.
    Kim, D.
    Kim, H.
    Kim, B.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2024, 144 (08) : S95 - S95
  • [27] Tyrosine Kinase 2 (TYK2) Allosteric Inhibitors To Treat Autoimmune Diseases
    Chang, Yu
    Xu, Shilin
    Ding, Ke
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (20) : 8951 - 8952
  • [28] Potent and Selective Tyk2 Inhibitor Highly Efficacious in Rodent Models of Inflammatory Bowel Disease and Psoriasis
    Miao, Wenyan
    Masse, Craig
    Greenwood, Jeremy
    Kapeller, Rosana
    Westlin, William
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [29] Targeting TYK2 to target tau
    Barranco, Caroline
    NATURE REVIEWS NEUROSCIENCE, 2025, 26 (01) : 2 - 2
  • [30] Safety and efficacy of dual TYK2 inhibitor and biologic therapy
    Guenin, S.
    Andrews, E.
    Lebwohl, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (11) : S334 - S334